Drug Discovery Phases (2)

Target Validation in Human Tissues, 3D Models and iPSCs

REPROCELL offers functional validation of disease targets using our human-relevant systems. Investigate the target's potential as a drug using fresh patient tissue or patient-specific iPSC-derived disease model cells.

Assess the Efficacy of Your Drug Candidate in Diseased and Healthy Tissue

  • Compare activation of potential target and functional response.
  • Explore differences in drug response between patients and relate responses to clinical histories.



COPD lung


Healthy lung



Patient-specific iPS Cell generation service

Custom iPSCs can be created by reprogramming patient samples (Fibroblast, Blood, Urine, etc.) with REPROCELL Stemgent’s exclusive StemRNA™-3rd Gen footprint-free RNA technology. Patient-specific iPSCs are a self-renewing and expandable cell population with potential to differentiate into virtually any cell type.

We also have the ability to provide precision genome-edited cells by working with our leading industry partners. The ability to model human diseases using iPSCs has revolutionized the ways in which we study monogenic, complex and epigenetic disorders, as well as early- and late-onset diseases.

iPSC-derived Differentiated Cells

REPROCELL offers iPSC-derived differentiated cardiac cells, hepatocytes, and neurons suitable for use in basic research as model systems for a variety of applications. Unlike primary cells which may come from random donors with variable genetic backgrounds, these iPSC-derived cells have strong lot-to-lot performance consistency.

REPROCELL also has the ability to prepare customized versions of iPSC-derived cell types as required.



StemRNA™ Cardio


StemRNA™ Neuro


StemRNA™ Hepato


Ask REPROCELL to source the diseased tissue of interest

  • Activate the potential target in a fresh, functional diseased tissue and measure the biological response
  • Explore differences in drug response between patients and relate responses to the patient’s clinical history
  • Generate customised 2D and 3D tissue models using iPSCs generated from patients with the diseased of interest
  • Conduct follow-up gene expression analysis or sequencing to relate the functional activation of the target to genotype